taking tesamorelin: Frequently asked questions

Not immediately, but rapidly. If fasting glucose rises above 126 mg/dL on two separate measurements or HbA1c crosses 6.5%, initiate a one-week rapid taper (reduce to 1mg daily for 7 days, then stop) while consulting your prescribing physician. Abrupt cessation can cause rebound hypoglycemia in rare cases as hepatic gluconeogenesis suppression from insulin rebound overshoots. Monitor fasting glucose every 3–4 days during the taper and for two weeks post-cessation to confirm normalization. If glucose remains elevated 21 days after stopping, the Tesamorelin unmasked pre-existing prediabetes rather than causing it.

Partially. Resistance training combined with caloric restriction can slow VAT reaccumulation by 30–40% compared to discontinuation without lifestyle intervention, but it won't prevent rebound entirely. A study from The Journal of Clinical Endocrinology & Metabolism tracked patients who maintained structured exercise programs post-cessation and found VAT regain averaged 40% of lost tissue at six months vs 65% in sedentary controls. The hormonal mechanisms driving visceral fat storage. Cortisol sensitivity, insulin resistance, adipocyte lipogenic enzyme expression. Persist after Tesamorelin withdrawal, and lifestyle modification can only modulate them, not eliminate them.

No. Rebound severity correlates with the absolute amount of VAT lost, not treatment duration. Patients who achieved 15–20% VAT reduction over three months experience the same rebound velocity as those who reached the same reduction over six months. The adipocytes don't remember how long they were suppressed; they respond to how much they were depleted. If you lost significant visceral fat in a short timeframe, expect proportional reaccumulation unless you implement metabolic bridge strategies during the post-cessation period.

Fatigue lasting 2–4 weeks after the final Tesamorelin dose is common, particularly in patients whose baseline IGF-1 was below 150 ng/mL before starting therapy. The sudden withdrawal of elevated GH pulses creates a temporary adaptation period where endogenous pulsatility hasn't fully recovered yet. Subjective energy levels, exercise recovery, and mood typically normalize by week 3–4 post-cessation. If fatigue persists beyond six weeks or worsens progressively, rule out concurrent thyroid dysfunction or anemia. GH withdrawal doesn't cause prolonged debilitation.

No formal re-titration is required if you resume within 90 days of stopping. Restart at your previous maintenance dose (typically 2mg daily) and monitor for injection site reactions and glucose changes during the first two weeks. If the gap exceeds 90 days, consider restarting at 1mg daily for one week to assess tolerance before increasing to 2mg. Extended discontinuation periods allow the pituitary axis to fully reset, and some patients report heightened side effects when resuming at full dose after prolonged breaks.